Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

This article explains how regulators distinguish between GMP and cGMP during inspections, why “current” compliance matters, and how governance gaps lead to inspection findings. It provides practical insight for quality, manufacturing, and compliance leaders preparing for regulatory revie
This article explores how regulators assess manufacturing quality systems during inspections, why governance failures drive critical observations, and how structured oversight improves inspection readiness, reduces compliance risk, and supports consistent decision-making across pharmaceutical operations.
This article explains how regulators assess the Pharmacovigilance System Master File during inspections, where governance gaps create audit findings, and why clear accountability, traceability, and inspection readiness determine long-term regulatory confidence.
An inspection-driven overview explaining how regulators assess benefit–risk narratives in PBRERs, where governance gaps trigger repeat findings, and how structured oversight across reporting cycles strengthens compliance and regulatory confidence in pharmacovigilance systems.
This article explains how regulators assess DSURs during clinical development, focusing on safety governance, benefit–risk assessment, and data consistency across trials. It highlights common inspection findings and shows how structured oversight reduces regulatory risk and inspection escalation.
Discover how working standards uphold quality, safety, and regulatory compliance in the pharmaceutical industry. Explore key components and best practices.
Explore how contract manufacturing is transforming the pharmaceutical landscape, offering scalability, cost-efficiency, and specialized expertise.
Isolators and RABS both play critical roles in modern aseptic manufacturing, but their regulatory expectations differ significantly. FDA, EU, and ISO guidelines emphasize risk-based design, validated control measures, and procedural discipline.
Pharmaceutical isolators have revolutionized aseptic manufacturing by offering a controlled, contamination-free environment that enhances both product safety and operator protection.
In response to the COVID-19 pandemic, the European Medicines Agency (EMA) adapted its vaccine approval processes, implementing rolling reviews and enhancing collaboration with health authorities. This post analyzes the EMA's pivotal role in granting conditional marketing authorizations for COVID-19 vaccines